肥胖检测指标与PCOS合并IR的相关研究
Correlation Study of Obesity Detection Index and PCOS Combined with IR
DOI: 10.12677/ACM.2024.143714, PDF,   
作者: 蒋梦铃, 林 琳:新疆医科大学第一附属医院妇产科学,新疆 乌鲁木齐
关键词: 多囊卵巢综合征肥胖胰岛素抵抗Polycystic Ovary Syndrome Corpulent Insulin Resistance
摘要: 多囊卵巢综合症(PCOS)是育龄期女性常见的生殖内分泌疾病,临床表现为月经异常、不孕、高雄激素血症或体征(多毛症,痤疮、脱发)、肥胖、胰岛素抵抗(IR)等。PCOS常伴有胰岛素抵抗,可引起糖脂代谢异常,从而使得2型糖尿病,高血压,心血管疾病的发生率升高。约50%~70%的PCOS患者存在IR,肥胖PCOS人群中IR可达75%,肥胖和PCOS共存更易发生IR和MS。持续存在IR及MS,其远期并发症如:2型糖尿病,高血压,心血管疾病的发生率也会升高。因此,对于IR的早期干预将有利于降低PCOS患者心血管疾病等远期并发症的发病风险。
Abstract: Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disease in women of childbearing age. The clinical manifestations include abnormal menstruation, infertility, hyper and rogenemia or signs (hirsutism, acne, alopecia), obesity, insulin resistance (IR), etc. PCOS is often ac-companied by insulin resistance, which can cause abnormal glucose and lipid metabolism, thus in-creasing the incidence of type 2 diabetes, hypertension, and cardiovascular diseases. About 50% to 70% of PCOS patients have IR, and the IR of obese PCOS patients can reach 75%. The coexistence of obesity and PCOS makes IR and MS more likely. Long-term complications such as type 2 diabetes, hypertension, and cardiovascular disease may also increase with the persistence of IR and MS. Therefore, early intervention for IR will help reduce the risk of cardiovascular disease and other long-term complications in PCOS patients.
文章引用:蒋梦铃, 林琳. 肥胖检测指标与PCOS合并IR的相关研究[J]. 临床医学进展, 2024, 14(3): 390-395. https://doi.org/10.12677/ACM.2024.143714

参考文献

[1] 王莉, 徐帅. 维生素D辅治对多囊卵巢综合征患者脂代谢及相关激素水平和抑郁情绪的影响[J]. 中国健康心理学杂志, 2018, 26(4): 539-544.
[2] 于玲玉, 孙振高. 多囊卵巢综合征表观遗传学发病机制的研究现状[J]. 中国妇幼保健, 2019, 34(16): 3852-3854.
[3] 李海明. 认识多囊卵巢综合征[J]. 人人健康, 2023(26): 40-41.
[4] Bhattacharya, K., Sengupta, P., Dutta, S., et al. (2021) Waist-to-Height Ratio and BMI as Predictive Mark-ers for Insulin Resistance in Women with PCOS in Kolkata, India. Endocrine, 72, 86-95. [Google Scholar] [CrossRef] [PubMed]
[5] Boyle, J.A.C., Norman, R., Dunbar, T. and O’dea, K. (2015) Polycystic Ovary Syndrome and Metabolic Syndrome in Indigenous Australian Women. Internal Medicine Journal, 45, 1247-1254. [Google Scholar] [CrossRef] [PubMed]
[6] Zaki, M., Basha, W., El-Bassyouni, H.T., et al. (2018) Evalua-tion of DNA Damage Profile in Obese Women and Its Association to Risk of Metabolic Syndrome, Polycystic Ovary Syndrome and Recurrent Preeclampsia. Genes & Diseases, 5, 367-373. [Google Scholar] [CrossRef] [PubMed]
[7] 夏琴琴, 陈爱琴, 李梅兰, 等. 胰岛素抵抗与多囊卵巢综合征患者性激素水平相关性分析[J]. 宁夏医学杂志, 2020, 42(1): 12-14.
[8] 袁莹莹, 赵君利. 多囊卵巢综合征流行病学特点[J]. 中国实用妇科与产科杂志, 2019, 35(3): 274-278.
[9] Grundy, S.M. (2016) Metabolic Syndrome Update. Trends in Cardiovascular Medicine, 26, 364-373. [Google Scholar] [CrossRef] [PubMed]
[10] Suren, G.S., Kushwaha, K., Dubey, R., et al. (2023) Association between Obesity, Inflammation and Insulin Resistance: Insights into Signaling Pathways and Therapeutic Interventions. Diabetes Research and Clinical Practice, 200, Article ID: 110691. [Google Scholar] [CrossRef] [PubMed]
[11] Rojas, J., et al. (2014) Polycystic Ovary Syndrome, Insulin Re-sistance, and Obesity: Navigating the Pathophysiologic Labyrinth. International Journal of Reproductive Medicine, 2014, Article ID: 719050. [Google Scholar] [CrossRef] [PubMed]
[12] Legro, R.S. (2012) Obesity and PCOS: Implications for Diagnosis and Treatment. Seminars in Reproductive Medicine, 30, 496-506. [Google Scholar] [CrossRef] [PubMed]
[13] 木良善, 赵越, 乔杰. 肥胖与多囊卵巢综合征的关联性及潜在机制[J]. 中华生殖与避孕杂志, 2018, 38(4): 343-349.
[14] Legro, R.S., Castracane, V.D. and Kauffman, R.P. (2004) Detecting Insulin Resistance in Polycystic Ovary Syndrome: Purposes and Pitfalls. Obstetrical & Gynecological Survey, 59, 141-154. [Google Scholar] [CrossRef
[15] Siddiqui, S., Mateen, S., Ahmad, R., et al. (2022) A Brief Insight into the Etiology, Genetics, and Immunology of Polycystic Ovarian Syndrome (PCOS). Journal of Assisted Reproduction and Genetics, 39, 2439-2473. [Google Scholar] [CrossRef] [PubMed]
[16] 王秀芳, 李茵, 邓海灵, 等. 肥胖型多囊卵巢综合征的慢病管理策略[J]. 中国妇幼保健, 2018, 33(20): 4569-4572.
[17] Zhu, S., Li, Z., Hu, C., et al. (2021) Imaging-Based Body Fat Distribution in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 12, Article ID: 697223. [Google Scholar] [CrossRef] [PubMed]
[18] Akopians, A.L., Madrigal, V., Fisch, S., et al. (2016) Hyper-androgenism Is Associated with Preferential Fat Deposition of Visceral versus Subcutaneous (SC) Abdominal Fat in Lean Polycystic Ovary Syndrome (PCOS) Women. Fertility and Sterility, 106, E31-E32. [Google Scholar] [CrossRef
[19] Zhao, H., Zhang, Y., Shu, L., et al. (2019) Resveratrol Reduc-es Liver Endoplasmic Reticulum Stress and Improves Insulin Sensitivity in Vivo and in Vitro. Drug Design, Development and Therapy, 13, 1473-1485. [Google Scholar] [CrossRef
[20] 赵玉雪. 代综方干预骨骼肌细胞胰岛素抵抗及其作用机制研究[D]: [博士学位论文]. 北京: 中国中医科学院, 2017.
[21] 刘玲玉. 薯蓣粥对2型糖尿病患者血清SOD、MDA的影响[D]: [硕士学位论文]. 福州: 福建中医药大学, 2016.
[22] Pang, Y. (2021) Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites. Metabolites, 11, Article No. 869. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, H., Wang, W., Zhao, J., et al. (2022) Relationship be-tween Body Composition, Insulin Resistance, and Hormonal Profiles in Women with Polycystic Ovary Syndrome. Fron-tiers in Endocrinology (Lausanne), 13, Article ID: 1085656. [Google Scholar] [CrossRef] [PubMed]
[24] Ye, W., Xie, T., Song, Y., et al. (2021) The Role of Androgen and Its Related Signals in PCOS. Journal of Cellular and Molecular Medicine, 25, 1825-1837. [Google Scholar] [CrossRef] [PubMed]
[25] 陈效琴, 俞安清, 张博林, 等. 肥胖及腹型肥胖人群的血清游离脂肪酸水平与胰岛素抵抗的关系研究[J]. 检验医学与临床, 2015, 12(19): 2917-2918.
[26] Yaribeygi, H., et al. (2018) Insulin Resistance: Review of the Underlying Molecular Mechanisms. Journal of Cellular Physiology, 234, 8152-8161. [Google Scholar] [CrossRef] [PubMed]
[27] 余鹏, 袁刚. 肥胖相关性胰岛素抵抗发生机制[J]. 华南国防医学杂志, 2017, 31(3): 213-217.
[28] Polymeris, A. and Papapetrou, P.D. (2022) Anthropometric Indicators of Insulin Resistance. Hormones (Athens), 21, 51-52. [Google Scholar] [CrossRef] [PubMed]
[29] 周昕玥, 魏林飞, 张学红. PCOS子宫内膜容受性障碍的机制与治疗研究进展[J]. 兰州大学学报(医学版), 2023, 49(1): 79-86.
[30] Huang, X., Wang, Q., Liu, T., et al. (2019) Body Fat Indices as Effective Predictors of Insulin Resistance in Obese/Non-Obese Polycystic Ovary Syndrome Women in the Southwest of China. Endocrine, 65, 81-85. [Google Scholar] [CrossRef] [PubMed]
[31] Ramezani Tehrani, F., Minooee, S. and Azizi, F. (2014) Com-parison of Various Adiposity Indexes in Women with Polycystic Ovary Syndrome and Normo-Ovulatory Non-Hirsute Women: A Population-Based Study. European Journal of Endocrinology, 171, 199-207. [Google Scholar] [CrossRef
[32] Glueck, C.J. and Goldenberg, N. (2019) Characteristics of Obesity in Polycystic Ovary Syndrome: Etiology, Treatment, and Genetics. Metabolism, 92, 108-120. [Google Scholar] [CrossRef] [PubMed]
[33] Goossens, G.H. (2017) The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function. Obesity Facts, 10, 207-215. [Google Scholar] [CrossRef] [PubMed]
[34] 席焕久, 李文慧, 刘莹莹. 体质测量在超重和肥胖研究中的应用[J]. 人类学学报, 2021, 40(2): 328-345.
[35] Bosomworth, N.J., et al. (2019) Normal-Weight Central Obesity: Unique Hazard of the Toxic Waist. Canadian Family Physician, 65, 399-408.
[36] Kahn, H.S. (2005) The “Lipid Accumulation Product” Performs Better than the Body Mass Index for Recognizing Cardiovascular Risk: A Population-Based Com-parison. BMC Cardiovascular Disorders, 5, Article No. 26. [Google Scholar] [CrossRef] [PubMed]
[37] Bozorgmanesh, M., Hadaegh, F. and Azizi, F. (2010) Predictive Per-formances of Lipid Accumulation Product vs. Adiposity Measures for Cardiovascular Diseases and All-Cause Mortality, 8.6-Year Follow-Up: Tehran Lipid and Glucose Study. Lipids in Health and Disease, 9, Article No. 45. [Google Scholar] [CrossRef
[38] Dai, H., Wang, W., Chen, R., et al. (2017) Lipid Accumulation Product Is a Powerful Tool to Predict Non-Alcoholic Fatty Liver Disease in Chinese Adults. Nutrition & Metabolism, 14, Article No. 49. [Google Scholar] [CrossRef] [PubMed]
[39] Folsom, A.R., Kushi, L.H., Anderson, K.E., et al. (2000) Associ-ations of General and Abdominal Obesity with Multiple Health Outcomes in Older Women: The Iowa Women’s Health Study. Archives of Internal Medicine, 160, 2117-2128. [Google Scholar] [CrossRef] [PubMed]
[40] 谢爱霞, 吴胜利, 李农, 等. 肥胖与糖尿病、高血压病的相关性探讨[J]. 中国糖尿病杂志, 2007, 15(9): 556-557.
[41] Amato, M.C., Giordano, C., Galia, M., et al. (2010) Visceral Adiposity Index: A Reliable Indicator of Visceral Fat Function Associated with Cardiometabolic Risk. Diabetes Care, 33, 920-922. [Google Scholar] [CrossRef] [PubMed]
[42] 张晶, 谷郁婷, 刘继波, 等. PCOS合并糖代谢异常患者全身脂肪含量及VATA的影响因素分析[J]. 中国保健营养, 2017, 27(19): 14.
[43] 张怡, 王禹盈, 徐文迪, 等. 多囊卵巢综合征患者内脏脂肪指数与糖调节受损独立正相关[J]. 中华糖尿病杂志, 2019, 11(4): 265-269.
[44] Wang, H., Cao, H., Cao, J., et al. (2023) The Visceral Adiposity Index (VAI) and Lipid Accumulation Product (LAP) Are Predictors of In-sulin Resistance and Hyperandrogenaemia in Obesity/Overweight Women with Polycystic Ovary Syndrome. BioMed Research International, 2023, Article ID: 1508675. [Google Scholar] [CrossRef] [PubMed]
[45] Shrivastava, S. and Conigliaro, R.L. (2023) Polycystic Ovarian Syndrome. Medical Clinics of North America, 107, 227-234. [Google Scholar] [CrossRef] [PubMed]